A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
BioXcel Therapeutics Inc
National Cancer Institute (NCI)
University of Utah
Taproot Health
RECORDATI GROUP
Stanford University
Merck Sharp & Dohme LLC